The Los Alamos National Laboratory has continued the development of the Optical Biopsy System (OBS) for noninvasive, real-time in situ diagnosis of tissue pathologies. In proceedings of earlier SPffi conferences we reported on clinical measurements in the bladder, and we report here on recent results of clinical tests in the gastrointestinal tract.
surgical environment required to take biopsy samples. Moreover, the immediacy of diagnostic information can reduce the emotional trauma to the patient waiting for an answer.
A range of spectroscopies have been investigated for optical diagnosis, all of which have one basic principle in common. The specific optical spectrum of a tissue sample contains information about the biochemical composition and/or the structure of the tissue. This basic approach is useful not only for the detection of cancer, but may also be used for detection and diagnosis of other tissue abnormalities such as atherosclerosis, endometriosis and infections.
While light scattering, fluorescence, and Raman spectroscopy have all been investigated as methods for distinguishing malignant tissue, the majority of work has utilized fluorescence spectroscopy. Fluorescence spectroscopy has been investigated with and without the aid of exogenous drugs that target malignant tissue. The fluorescence from such drugs provides a large signal, which can be helpful in the detection process1 and may be used as a detection tool for CCD imaging of the patterns of malignancy in a given area of tissue. This, however, is not an ideal solution for routine examination, since the administration of an exogenous drug is essentially an invasive process and can result in concomitant undesirable side affects. An alternative is to use intrinsic (usually UV-induced) tissue fluorescence, or autofluorescence, as a diagnostic tool.23 '4 Many researchers have pursued this approach, including, for example, Svanberg et al. who have investigated in vivo autofluorescence in several areas of the body including the brain, bladder and oral cavity.5 The results from the few studies involving large sample sets demonstrate levels of reliability that range from very good (>90%, with minimal false negatives) to the unacceptable (<75%, with a significant fraction of false negatives).
Although Raman spectroscopy provides a much weaker signal than fluorescence, it has the advantage of sharp spectral features, which are more easily correlated with specific chemical components. While early studies with Raman spectroscopy invoked costly and slow instrumentation (data collection times of 15 Raman spectroscopy show promise, larger sample sizes will be needed for conclusive results, and instrumentation remains expensive.
With the OBS, tissue pathologies are detected/diagnosed using spectral measurements of the elastic optical transport properties (scattering and absorption) of the tissue over a wide range of wavelengths. The probe is designed to be used in optical contact with the tissue under examination and has separate illuminating and collecting fibers. Thus, the light that is collected and transmitted to the analyzing spectrometer must first scatter through a small volume of the tissue before entering the collection fiber(s). Consequently, the system is also sensitive to the optical absorption spectrum of the tissue, over an effective operating range of 300 to 800 nm, and such absorption adds valuable complexity to the scattering spectral signature. The data acquisition and storage/display time with the OBS instrument is <1 second. Thus, in addition to the reduced invasiveness of this technique compared with current state-of-the-art methods (surgical biopsy and pathology analysis), the OBS offers the possibility of impressively faster diagnostic assessment. It is important to note that the OBS probe, being used in optical contact with the tissue, examines only that site and does not image the tissue surface. More detailed discussions of the technology have appeared in earlier publications.9'10'11
Caution: It should be noted that researchers addressing any new approach to tissue diagnosis, including optical spectroscopy, are faced with a general problem in determining the efficacy of the new method. Schomaker et al. 4 point out that when three pathologists examined the same 91 polyp samples, a given pathologist's diagnosis was in the majority about 90% of the time. If the "gold standard" is not perfect, it is difficult to determine the accuracy of the optical measurement. Applying a dichotomous diagnostic algorithm is also difficult. For example, the autofluorescence spectra of malignant and nonmalignant tissues tend to form a continuum between malignant and nonmalignant. The exact form of the algorithm may depend on which patients were included in a particular study.
ELASTIC SCATTERING SPECTROSCOPY
Efforts by other groups to utilize elastic scattering spectroscopy for tissue diagnosis have focused mainly on diffuse reflection from the surface of ki31415 Their results have shown limited reliability in detecting cancer, in our judgment because of the interference of melanin and the vagaries of specular reflection from the tissue surface. The intent of our approach is to generate spectral signatures of closer relevance to the tissue parameters that a pathologists addresses. After preparing a slide, a pathologist performs a microscopic assessment (histopathology) of the cell architecture or morphology: the sizes and shapes of cells, the ratio of nuclear to cellular volume, the form of the bilipid membrane, clustering patterns, etc. These changes will have an effect on the elastic scattering properties, separate from any inelastic process, such as fluorescence or Raman scattering. The angular distribution of scattering will have a wavelength dependence that is affected by the cellular architecture. The increased photon pathlengths in tissue, induced by multiple scattering, also accentuate the effect of spectral absorption bands. Thus, our approach to the problem is to generate a signature that comprises data from the elastic scattering and absorption -the elastic optical transport properties of the tissue.
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The optical geometry of our fiber-optic probe is relation to the tissue is shown in Figure 1 . It is critical to note that the fiber-optic probe is used in optical contact with the tissue. Thus, surface reflection is purposefully avoided, and all light reaching the collection fiber(s) has undergone multiple scattering through a distance of tissue. Each of the fibers is typically 200-400 microns in diameter, and the entire probe, including jacket, can be less than 1 mm diameter. Broadband "white" light (.'3OO-8OO nm) enters the tissue from the illumination fiber(s). The wavelength dependence of the light that manages to reach the collection fiber will be a function of both the elastic scattering and absorption properties of the tissue, and such spectral variations form the basis of the signatures used for detection/diagnosis by the OBS. As illustrated in the figure, the effective pathlength (through tissue) of photons entering the collection fiber can be many times greater than the simple distance between the emitting and collecting fibers. Thus, the sensitivity of the system to spectral absorption bands is enhanced.
The details of the system concept and design of the Optical Biopsy System have been described in various earlier 91'16 For the parameters relevant to mammalian tissue, the physics of the scattering interactions are best described by Mie scattering theory. The use of this theory in Monte Carlo numerical simulations of the photon density patterns has been described in Reference 10.
CLINICAL TESTING
Our earlier clinical studies (on bladder cancer) were reported in References 1 1 and 1 6. Certain spectral features were found to correlate well with the pathological diagnoses. Our recent clinical studies have begun to address various regions of the gastrointestinal tract. About 25 patients were examined at two clinical sites. Since instrument changes were made in the Optical Biopsy System between use at the two sites, and because of possible systematic differences in the pathology analysis at the two institutions, spectra from the two sites are not directly compared. Even with two clinical sites all of the data that follow represent small numbers of patients for each type of pathology, and hence are not presented on a statistical basis. Thus, we do not make any claims at this point regarding the reliability/efficacy for GI pathologies, as more rigorous FDA trials are required. The main intent is to show the potential for OBS spectral signature identification in these new regions, which are of great importance to medical practice. In general, separate studies with a larger statistical base are required to demonstrate reliable efficacy in the detection and diagnosis of pathologies for each new organ area of interest and for each type of pathology. FONET, Inc., a company in Clearwater, Florida, has licensed the patented technology of the OBS system from the Los Alamos National Laboratory, and will soon proceed in gathering much larger statistical bases of data for FDA approval.
Duodenal data
Data were taken at a number of sites of duodenal polyps with two patients. Figure 2 shows data from one of the patients. There is a notable trend, that the ratio of the elastic scatter signal at -630 nm to that at 575 nm is smaller for adenomas than for non-adenomatous tissue. Traces 100 and 101 were taken from putative normal mucosa sites, while 102 through 105 were frank polyps. This metric is an interesting one in that the dips in the spectra at 542 and 579 nm are due to hemoglobin absorption. One might conclude that there is simply more Hb in the malignant tissue. However, the dip at -420 nm is also due to Hb and this does not vary significantly. It should also be noted that trace 104 in Fig. 2 was for a polyp that appeared no different clinically (to the eye) than the other polyps, but was evidently hyperplastic. Its spectral signature follows the same path as adenomatous poiyps in the UV region, but follows the normal sites in the 550-650 nm range. Thus, this meager amount of data would suggest that the 550-650 spectral region may provide the more reliable correlation with pathological changes of concern. Colon data
Optical biopsy measurements were made in the colons of 10 patients. Of the 25 biopsy sites one was malignant, and two were adenomas. Fig. 3 shows that it may be possible to separate malignant and adenomatous from other diagnoses by using multiple metrics. The x-axis is the integrated signal from 630 to 670 nm divided by the integrated signal from 540to 580 nm. The y-axis is the integrated signal from 630 to 670nm divided by the integrated signal from 400 to 440 nm. Both of these ratios involve hemoglobin absorption bands. In general it is expected both ratios would increase together. What is interesting about Figure 3 , however, is that as the value of the ratio involving the Soret band, for a given value of the ratio involving the alpha and beta bands, is not as great for the adenomatous and malignant as for other diagnoses.
Other metrics are being investigated, and, again, continuing studies will benefit from more data.
Rectal polyps Figure 4 shows spectra from the rectum of one patient in Wisconsin. Operator error with the recording computer caused the loss of data in the spectral range of 440 to 540nm. Nonetheless, the salvaged data on either side show repeated signature differences between pathology reports indicating adenoma vs. normal sites. Note the similarity in the 550 -650 nm range with the duodenal data. Barret's esophagus OBS measurements were made on several patients with Barret's esophagus. From this data there is some indication that we might be able to separate Barret's with dysplasia from Barret's without dysplasia. Fig. 5 shows the results of one particular metric applied to the data taken in Oklahoma. 
CONCLUSIONS
An initial set of studies have been carried out on various regions of the gastrointestinal tract. The main purpose of this initial round of measurements was to provide guidance for expanded studies of the efficacy of the Optical Biopsy System in this area. Nonetheless, these initial studies indicate promise for this convenient and low-cost diagnostic technology. Formal FDA testing is expected to begin in February of 1995.
"Teething pains" encountered with this new-generation, low-cost version of the OBS system are being corrected. These include the spectral illumination-lamp stability, computer operating software, and an appropriate method for keeping the tip of the fiber probe clean once it is inside the GI tract. Commercial development of the instrument will speed the engineering of system details and user friendliness. 
